Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins revealed marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide.

不同国家批准了不同的 SARS-CoV-2 疫苗，但很少有直接比较它们刺激的抗体反应的报道。我们于 2021 年 7 月从 196 名完全接种了四种 COVID-19 疫苗之一的蒙古参与者那里收集了血浆样本：辉瑞/BioNTech、阿斯利康、Sputnik V 和国药。使用一组 9 种 SARS-CoV-2 病毒变异受体结合域 (RBD) 蛋白进行的功能性抗体测试显示疫苗反应存在显着差异，国药和 Sputnik V 疫苗刺激的抗体水平和 RBD-ACE2 阻断活性与阿斯利康或辉瑞/BioNTech 疫苗。2021 年 6 月和 2021 年 7 月初，Alpha 变种导致了蒙古 97% 的感染。在大多数情况下，接种疫苗后从 SARS-CoV-2 感染中康复的个体会获得高抗体滴度。这些数据表明，为了在蒙古和全世界控制 COVID-19，可能需要采取公共卫生干预措施，例如加强疫苗接种（可能使用更有效的疫苗类型）。